Circulating endothelial progenitor cells as potential prognostic biomarker in multiple myeloma

Leukemia and Lymphoma

Volumn 53, Issue 4, 2012, Pages 635-640

  Bhaskar, Archana ^a   Gupta, Ritu ^a   Kumar, Lalit ^a   Sharma, Atul ^a   Sharma, Mehar Chand ^b   Kalaivani, Mani ^b   Thakur, Sonu Chand ^c  

^a INSTITUTE ROTARY CANCER HOSPITAL   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^c JAMIA MILLIA ISLAMIA CENTRAL UNIVERSITY   (India)

Author keywords

Angiogenesis; Biomarker; Circulating endothelial progenitor cells (cEPCs); Multiple myeloma (MM)

Indexed keywords

CD133 ANTIGEN; CD31 ANTIGEN; CD34 ANTIGEN;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; ENDOTHELIAL PROGENITOR CELL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL COUNT; DISEASE-FREE SURVIVAL; ENDOTHELIAL CELLS; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; STEM CELLS; TREATMENT OUTCOME;

EID: 84859046609     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.628880     Document Type: Article

References (21)

1. Vacca A, Ribatti D, Roncali L, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994;87:503-508.
2. Rajkumar SV, Mesa RA, Fonseca R, et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined signifi cance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 2002;8:2210-2216.
3. Anderson KC. Moving disease biology from the lab to the clinic. Cancer 2003;97:796-801.
4. Sato Y. Molecular diagnosis of tumor angiogenesis and antiangiogenic cancer therapy. Int J Clin Oncol;2003;8:200-206.
5. Kropff M, Bisping G, Wenning D, et al. Proteasome inhibition in multiple myeloma. Eur J Cancer 2006;42:1623-1639.
6. Laubach JP, Mahindra A, Mitsiades CS, et al. The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia 2009;23:2222-2232.
7. Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010;24:22-32.
8. Mancuso P, Burlini A, Pruneri G, et al. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 2001;97:3658-3661.
9. Beerepoot LV, Mehra N, Vermaat JS, et al. Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann Oncol 2004;15:139-145.
10. Naik RP, Jin D, Chuang E, et al. Circulating endothelial progenitor cells correlate to stage in patients with invasive breast cancer. Breast Cancer Res Treat 2008;107:133-138.
11. Nowak K, Rafat N, Belle S, et al. Circulating endothelial progenitor cells are increased in human lung cancer and correlate with stage of disease. Eur J Cardiothorac Surg 2010;37:758-763.
12. Peichev M, Naiyer AJ, Pereira D, et al. Expression of VEGFR-2 and AC133 by circulating human CD34 (+ ) cells identifies a population of functional endothelial precursors. Blood 2000;95:952-958.
13. Mauro E, Rigolin GM, Fraulini C, et al. Mobilization of endothelial progenitor cells in patients with hematological malignancies after treatment with fi lgrastim and chemotherapy for autologous transplantation. Eur J Hematol 2007;8:374-380.
14. Duda DG, Cohen KS, Scadden DT, et al. A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood. Nat Protoc 2007;2:805-810.
15. Case J, Mead LE, Bessler WK, et al. Human CD34+ AC133+ VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp Hematol 2007; 35: 1109-1118.
16. Yoder MC, Mead LE, Prater DL, et al. Redefi ning endothelial progenitor cells via clonal analysis and hematopoietic stem progenitor cell principals. Blood 2007;109:1801-1809.
17. Durie BGM, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20: 1467-1473.
18. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-3420.
19. Zhang H, Vakil V, Braunstein M, et al. Circulating endothelial progenitor cells in multiple myeloma: Implications and signifi cance. Blood 2005;105:3286-3294.
20. Bhatti SS, Kumar L, Dinda AK, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma: Use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological and laboratory parameters. Am J Hematol 2006; 81:649-656.
21. Rajkumar SV, Leong T, Roche PC, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 2000; 6:3111-3116.